Digital Healthcare / Prescription Price Transparency / Healthcare Technology
Strategic Profile
The company reported marginal revenue and EBITDA growth for 2025, with the business mix shifting rapidly toward high-margin Pharma Direct offerings and away from its legacy prescription transactions. Management described a business model transformation, prioritizing direct-to-consumer and employer-integrated pricing platforms, and locking in long-term partnerships with retail pharmacies. The company is increasingly orienting around its Pharma Manufacturer Solutions business—now rebranded as GoodRx Pharma Direct—as a key growth driver.
Cyborg Score Rationale
GoodRx reported marginal revenue and EBITDA growth for 2025, with the company's 2026 revenue outlook acknowledging notable headwinds from continued pressure on prescription transaction fees and the loss of volume due to external partner disruptions. However, Pharma Direct grew 41% year-over-year, underscoring the strategic progress being made as the company repositions.
Top Insights
Company expects Pharma Direct revenue to grow at least 30% in 2026.
GoodRx launched GoodRx Employer Direct on February 24, 2026, offering employers targeted subsidies to lower employee out-of-pocket costs for high-impact brand medications, including GLP-1s like Wegovy. Employer Direct also offers branded telemedicine solutions that integrate clinical care, prescribing, and pharmacy fulfillment.
GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications including over 30 of Pfizer's essential brand medications.
Monthly active consumers fell 14% in 2025 versus the prior year, with sequential flattening projected but no near-term return to prior user levels.